EUVIMEDScopri EUVIMED
Randomisierte kontrollierte Studie

Efficacy and Safety of Oral Oseltamivir for Influenza Prophylaxis in Transplant Recipients

Michael G Ison, Peter Szakaly, Michael Y Shapira, Gergely Kriván, Ann Nist, Regina Dutkowski

Antiviral Therapy · 2012-08 · 17 (6) · 955-964

DOI: 10.3851/imp2192 ↗

At a glance

Randomisierte kontrollierte Studie in Antiviral Therapy, published online on 2012-08-01. Written by Michael G Ison and 5 co-authors. Institution: Divisions of Infectious Diseases and Organ Transplantation, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. mgison@northwester…. Major MEDLINE topics: Hematopoietic Stem Cell Transplantation, Kidney Transplantation, Liver Transplantation. Cited 68 times so far (Crossref); 53 references.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Background

Haematopoietic stem cell transplant (HSCT) and solid organ transplant (SOT) recipients are at high risk for severe influenza and its complications, and may not be adequately protected by vaccination.

Methods

Liver, kidney, or liver–kidney transplant or allogeneic HSCT recipients aged ≥1 year were randomized to oseltamivir (75 mg once daily for those ≥13 years or weight-based dosing for children 1–12 years) or placebo for 12 weeks during periods of local influenza circulation. Patients were assessed for influenza infection via daily diary, every-other-week culture and PCR, and baseline and end-of-treatment serology.

Results

A total of 477 subjects were enrolled (239 oseltamivir and 238 placebo); most were adults (96%) and SOT recipients (81%). In the intent-to-treat population, the frequency of laboratory-confirmed clinical influenza (culture positive and/or >4-fold increase in haemagglutinin antibody inhibition [primary end point]) was similar in the oseltamivir and placebo groups (2.1% [5/237] and 2.9% [7/238]). Incidence of laboratory-confirmed influenza was significantly reduced in the oseltamivir group versus placebo when determined by reverse transcriptase-PCR (1.7% [4/237] versus 8.4% [20/238]; 95% CI 2.8, 11.1) or viral culture (

Subjects

MeSH terms (MEDLINE)

Hematopoietic Stem Cell TransplantationKidney TransplantationLiver TransplantationAdministration, OralAdolescentAdultAgedAntiviral AgentsChildChild, PreschoolFemaleHumansIncidenceInfantInfluenza A Virus, H1N1 SubtypeInfluenza, HumanMaleMiddle AgedOseltamivirProspective StudiesReverse Transcriptase Polymerase Chain ReactionYoung Adult

Substances

Antiviral AgentsOseltamivir

Authors and institutions

  • Divisions of Infectious Diseases and Organ Transplantation, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. mgison@northwestern.edu

Cite

APA

Ison, M. G., Szakaly, P., Shapira, M. Y., Kriván, G., Nist, A., & Dutkowski, R. (2012). Efficacy and Safety of Oral Oseltamivir for Influenza Prophylaxis in Transplant Recipients. Antiviral Therapy, 17(6), 955-964. https://doi.org/10.3851/imp2192

Vancouver

Ison MG, Szakaly P, Shapira MY, Kriván G, Nist A, Dutkowski R. Efficacy and Safety of Oral Oseltamivir for Influenza Prophylaxis in Transplant Recipients. Antiviral Therapy. 2012;17(6):955-964. doi:10.3851/imp2192

BibTeX
@article{Ison2012,
  author = {Ison, Michael G and Szakaly, Peter and Shapira, Michael Y and Kriván, Gergely and Nist, Ann and Dutkowski, Regina},
  title = {Efficacy and Safety of Oral Oseltamivir for Influenza Prophylaxis in Transplant Recipients},
  journal = {Antiviral Therapy},
  year = {2012},
  volume = {17},
  number = {6},
  pages = {955--964},
  doi = {10.3851/imp2192}
}
Start for free →